{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:26:11Z","timestamp":1763529971443,"version":"3.45.0"},"reference-count":47,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UID\/00006\/2023","UID\/04561\/2025"],"award-info":[{"award-number":["UID\/00006\/2023","UID\/04561\/2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mathematics"],"abstract":"<jats:p>Background: Liver transplantation is the most effective curative treatment for patients with hepatocellular carcinoma. Due to the scarcity of cadaveric donor livers, several selection criteria have been established; however, these criteria are highly restrictive. In this study, we compare alternative selection tools with the standard selection criterion, the Milan Criteria. We conducted a cost-effectiveness analysis from the perspective of the U.S. healthcare system to determine which criterion provides the greatest benefit to the health system. Methods: An innovative non-homogeneous Markov model was developed to simulate the health trajectories of patients with hepatocellular carcinoma who underwent liver transplantation over five years. The model incorporated time-dependent transition probabilities, enabling the simulation to capture the evolving risks of recurrence and mortality. Transition probabilities, costs, and QALYs were obtained from published studies, while recurrence probabilities were estimated using the Kaplan\u2013Meier method based on a cohort of 149 patients. We evaluated mean recurrence-free survival, life years gained, quality of life, and the incremental cost-effectiveness ratio (ICER) relative to the Milan Criteria. Results: HepatoPredict yielded the most significant benefits but incurred higher total costs than the other criteria. The ICERs of HepatoPredict Class I and Class II relative to the MC were $14,689.58\/QALY and $39,542.98\/QALY, respectively. Both values were below the cost-effectiveness threshold (U.S. GDP per capita: $81,632.25\/QALY), indicating that HepatoPredict is cost-effective in the U.S. healthcare system. Conclusions: HepatoPredict stands out as the most cost-effective criterion and optimises organ allocation, an especially important consideration given the scarcity of donor livers. This represents a substantial advantage for healthcare institutions.<\/jats:p>","DOI":"10.3390\/math13223683","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:05:31Z","timestamp":1763463931000},"page":"3683","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of Markov Models to Cost-Effectiveness Analysis in the Selection of Patients for Liver Transplantation"],"prefix":"10.3390","volume":"13","author":[{"given":"Hugo","family":"Pereira","sequence":"first","affiliation":[{"name":"Departamento de Ci\u00eancias Matem\u00e1ticas, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-0285","authenticated-orcid":false,"given":"Raquel J.","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Departamento de Ci\u00eancias Matem\u00e1ticas, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"},{"name":"Center for Mathematical Studies, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"}]},{"given":"Helena","family":"Mouri\u00f1o","sequence":"additional","affiliation":[{"name":"Departamento de Ci\u00eancias Matem\u00e1ticas, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"},{"name":"CEAUL\u2014Centro de Estat\u00edstica e Aplica\u00e7\u00f5es, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today (Version 1.1), International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2019.04.043","article-title":"Hepatocellular carcinoma incidence is decreasing among younger adults in the United States","volume":"18","author":"Rich","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cgh.2018.05.039","article-title":"Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma","volume":"17","author":"Rich","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","unstructured":"World Health Organization (2016). International Agency for Research on Cancer Cancer Today, World Health Organization."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1245\/s10434-022-12242-4","article-title":"Critical analysis of the updated Barcelona clinic liver cancer (BCLC) group guidelines","volume":"29","author":"Tsilimigras","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6002\/ect.2017.0303","article-title":"Comparison of resection and liver transplant in treatment of hepatocellular carcinoma","volume":"18","author":"Aksoy","year":"2020","journal-title":"Exp. Clin. Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e5904","DOI":"10.1097\/MD.0000000000005904","article-title":"Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities","volume":"96","author":"Golabi","year":"2017","journal-title":"Medicine"},{"key":"ref_10","first-page":"1038","article-title":"Hepatocellular Carcinoma Nat Rev Dis Primers. 7: 6","volume":"1038","author":"Llovet","year":"2021","journal-title":"Article10"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"zrac024","DOI":"10.1093\/bjsopen\/zrac024","article-title":"Selection criteria in liver transplantation for hepatocellular carcinoma: An ongoing evolution","volume":"6","author":"Line","year":"2022","journal-title":"BJS Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/SLA.0000000000005637","article-title":"A gene expression signature to select hepatocellular carcinoma patients for liver transplantation","volume":"276","author":"Cardoso","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: A model including \u03b1-fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"New Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_19","unstructured":"(2025, April 12). Ophiomics\u2014Precision Medicine. Available online: https:\/\/www.ophiomics.com\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1258\/135581904322987535","article-title":"Modelling in the economic evaluation of health care: Selecting the appropriate approach","volume":"9","author":"Barton","year":"2004","journal-title":"J. Health Serv. Res. Policy"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-P\u00e9riz, I., Barrachina-Mart\u00ednez, I., D\u00edaz-Carnicero, J., Climent, A.M., and Vivas-Consuelo, D. (2023). Cost-Effectiveness Mathematical Model to Evaluate the Impact of Improved Cardiac Ablation Strategies for Atrial Fibrillation Treatment. Mathematics, 11.","DOI":"10.3390\/math11040915"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jval.2025.01.019","article-title":"Mapping the Landscape of Open Source Health Economic Models: A Systematic Database Review and Analysis: An ISPOR Special Interest Group Report","volume":"28","author":"Henderson","year":"2025","journal-title":"Value Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5694\/mja2.52385","article-title":"The economics of a national anterior cruciate ligament injury prevention program for amateur football players: A Markov model analysis","volume":"221","author":"Ross","year":"2024","journal-title":"Med. J. Aust."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13561-025-00611-0","article-title":"Cost-effectiveness analysis of combination therapies involving novel agents for first\/second-relapse patients with multiple myeloma: A Markov model approach with calibration techniques","volume":"15","author":"Wu","year":"2025","journal-title":"Health Econ. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wen, C., Wang, X., Shu, J., Ruan, Y., Xie, J., Cheng, X., Qi, B., En, H., Qin, G., and Huang, L. (2025). Estimated cost-effectiveness of early screening strategies for newborn hearing impairment using a Markov model. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1498860"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23814683251344962","DOI":"10.1177\/23814683251344962","article-title":"A Health Economic Evaluation of Routine Hepatocellular Carcinoma Surveillance for People with Compensated Cirrhosis to Support Australian Clinical Guidelines","volume":"10","author":"Worthington","year":"2025","journal-title":"MDM Policy Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101789","DOI":"10.1016\/j.aohep.2025.101789","article-title":"Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)","volume":"30","author":"Younossi","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/13696998.2023.2248840","article-title":"Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: A US cost-effectiveness analysis","volume":"26","author":"Patel","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/LVT.0000000000000249","article-title":"Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant","volume":"30","author":"Wu","year":"2024","journal-title":"Liver Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rognoni, C., Ciani, O., Sommariva, S., Bargellini, I., Bhoori, S., Cioni, R., Facciorusso, A., Golfieri, R., Gramenzi, A., and Mazzaferro, V. (2018). Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: A budget impact analysis. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4636-7"},{"key":"ref_31","unstructured":"Perelman, J., Soares, M., Mateus, C., Duarte, A., Faria, R., Ferreira, L., Saramago, P., Veiga, P., Furtado, C., and Caldeira, S. (2019). Methodological Guidelines for Economic Evaluation Studies of Health Technologies, INFARMED\u2014National Authority of Medicines and Health Products, IP."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4254\/wjh.v10.i11.837","article-title":"Decision modelling for economic evaluation of liver transplantation","volume":"10","author":"Qu","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Prosser, L.A.; et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-Effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost\u2013effectiveness thresholds: Pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull. World Health Organ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/1475-6773.14116","article-title":"Alternatives to the quality-adjusted life year: How well do they address common criticisms?","volume":"58","author":"Rand","year":"2023","journal-title":"Health Serv. Res."},{"key":"ref_37","unstructured":"Anchisi, M. (2011). M\u00e9todos N\u00e3o Param\u00e9tricos Para An\u00e1lise de Dados de Sobreviv\u00eancia. [Master\u2019s Thesis, Faculdade de Ci\u00eancias, Universidade de Lisboa]."},{"key":"ref_38","unstructured":"Rocha, C., and Papoila, A.L. (2009). An\u00e1lise de Sobreviv\u00eancia, Sociedade Portuguesa de Estat\u00edstica, SPE."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ajt.2024.01.014","article-title":"OPTN\/SRTR 2022 annual data report: Liver","volume":"24","author":"Kwong","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/liv.14736","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort","volume":"41","author":"Maccali","year":"2021","journal-title":"Liver Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/lt.20128","article-title":"Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis","volume":"10","author":"Roayaie","year":"2004","journal-title":"Liver Transplant."},{"key":"ref_42","unstructured":"Pereira, H. (2025). Cost-Effectiveness Analysis of Selection Criteria for Liver Transplantation in Patients with Hepatocellular Carcinoma. [Master\u2019s Thesis, Faculdade de Ci\u00eancias, Universidade de Lisboa]."},{"key":"ref_43","unstructured":"U.S. Bureau of Labor Statistics (2024, July 18). CPI Inflation Calculator, Available online: https:\/\/www.bls.gov\/data\/inflation_calculator.htm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1023\/A:1018815802500","article-title":"Ultrasound-Guided Liver Biopsy for Parenchymal Liver Disease (An Economic Analysis)","volume":"43","author":"Younossi","year":"1998","journal-title":"Dig. Dis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.28961","article-title":"Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States","volume":"65","author":"Cadier","year":"2017","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Andrade, R., Perez-Rojas, J., da Silva, S.G., Miskinyte, M., Quaresma, M.C., Fraz\u00e3o, L.P., Peixoto, C., Cubells, A., Montalv\u00e1, E.M., and Figueiredo, A. (2025). HepatoPredict Accurately Selects Hepatocellular Carcinoma Patients for Liver Transplantation Regardless of Tumor Heterogeneity. Cancers, 17.","DOI":"10.3390\/cancers17030500"},{"key":"ref_47","unstructured":"O\u2019Neill, A. (2024, July 18). Gross Domestic Product (GDP) per Capita in the United States in Current Prices from 1987 to 2029. Available online: https:\/\/www.statista.com\/statistics\/263601\/gross-domestic-product-gdp-per-capita-in-the-united-states\/."}],"container-title":["Mathematics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-7390\/13\/22\/3683\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:24:19Z","timestamp":1763529859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-7390\/13\/22\/3683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":47,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["math13223683"],"URL":"https:\/\/doi.org\/10.3390\/math13223683","relation":{},"ISSN":["2227-7390"],"issn-type":[{"type":"electronic","value":"2227-7390"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}